Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?
Robert S
RS
Wallis
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage* / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D012294:Rifamycins / Q000494:pharmacology; D055502:Secondary Prevention; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D012294:Rifamycins; D012293:Rifampin; C018421:rifapentine